Literature DB >> 28555414

Germline ETV6 mutations and predisposition to hematological malignancies.

Simone Feurstein1,2, Lucy A Godley3,4.   

Abstract

Patients with thrombocytopenia 5 have an autosomal dominant disorder of decreased platelet number with tendency to bleed, usually presenting in childhood, and have been found to have germline mutations in ETV6, which encodes a master hematopoietic transcription factor. Some patients who present similarly have inherited mutations in RUNX1 or ANKRD26. All three germline syndromes are also associated with a predisposition to myelodysplastic syndrome (MDS) and acute leukemia (AL). Since the first description of germline ETV6 mutations, 18 families have been reported. The common phenotype is mild to moderate thrombocytopenia with a variable predisposition to acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and MDS. This review will focus upon the role of ETV6 in hematopoiesis, especially in myeloid differentiation and maturation, and will describe the functional effects of mutant ETV6. The review will also provide an overview of common clinical features as well as recommendations for patient screening and follow-up and will debate whether additional clinical features should be included with the germline ETV6 syndrome.

Entities:  

Keywords:  Acute leukemia; ETV6; Germline; Predisposition; Thrombocytopenia

Mesh:

Substances:

Year:  2017        PMID: 28555414     DOI: 10.1007/s12185-017-2259-4

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  42 in total

1.  TEL is a sequence-specific transcriptional repressor.

Authors:  R G Lopez; C Carron; C Oury; P Gardellin; O Bernard; J Ghysdael
Journal:  J Biol Chem       Date:  1999-10-15       Impact factor: 5.157

2.  Yolk sac angiogenic defect and intra-embryonic apoptosis in mice lacking the Ets-related factor TEL.

Authors:  L C Wang; F Kuo; Y Fujiwara; D G Gilliland; T R Golub; S H Orkin
Journal:  EMBO J       Date:  1997-07-16       Impact factor: 11.598

Review 3.  ETV6 fusion genes in hematological malignancies: a review.

Authors:  Etienne De Braekeleer; Nathalie Douet-Guilbert; Frédéric Morel; Marie-Josée Le Bris; Audrey Basinko; Marc De Braekeleer
Journal:  Leuk Res       Date:  2012-05-12       Impact factor: 3.156

4.  Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia.

Authors:  W J Song; M G Sullivan; R D Legare; S Hutchings; X Tan; D Kufrin; J Ratajczak; I C Resende; C Haworth; R Hock; M Loh; C Felix; D C Roy; L Busque; D Kurnit; C Willman; A M Gewirtz; N A Speck; J H Bushweller; F P Li; K Gardiner; M Poncz; J M Maris; D G Gilliland
Journal:  Nat Genet       Date:  1999-10       Impact factor: 38.330

5.  Clinical effect of point mutations in myelodysplastic syndromes.

Authors:  Rafael Bejar; Kristen Stevenson; Omar Abdel-Wahab; Naomi Galili; Björn Nilsson; Guillermo Garcia-Manero; Hagop Kantarjian; Azra Raza; Ross L Levine; Donna Neuberg; Benjamin L Ebert
Journal:  N Engl J Med       Date:  2011-06-30       Impact factor: 91.245

6.  DNA binding by the ETS protein TEL (ETV6) is regulated by autoinhibition and self-association.

Authors:  Sean M Green; H Jerome Coyne; Lawrence P McIntosh; Barbara J Graves
Journal:  J Biol Chem       Date:  2010-04-16       Impact factor: 5.157

7.  Tel/Etv6 is an essential and selective regulator of adult hematopoietic stem cell survival.

Authors:  Hanno Hock; Eliza Meade; Sarah Medeiros; Jeffrey W Schindler; Peter J M Valk; Yuko Fujiwara; Stuart H Orkin
Journal:  Genes Dev       Date:  2004-09-15       Impact factor: 11.361

8.  Germline ETV6 Mutations Confer Susceptibility to Acute Lymphoblastic Leukemia and Thrombocytopenia.

Authors:  Sabine Topka; Joseph Vijai; Michael F Walsh; Lauren Jacobs; Ann Maria; Danylo Villano; Pragna Gaddam; Gang Wu; Rose B McGee; Emily Quinn; Hiroto Inaba; Christine Hartford; Ching-Hon Pui; Alberto Pappo; Michael Edmonson; Michael Y Zhang; Polina Stepensky; Peter Steinherz; Kasmintan Schrader; Anne Lincoln; James Bussel; Steve M Lipkin; Yehuda Goldgur; Mira Harit; Zsofia K Stadler; Charles Mullighan; Michael Weintraub; Akiko Shimamura; Jinghui Zhang; James R Downing; Kim E Nichols; Kenneth Offit
Journal:  PLoS Genet       Date:  2015-06-23       Impact factor: 5.917

9.  COSMIC: exploring the world's knowledge of somatic mutations in human cancer.

Authors:  Simon A Forbes; David Beare; Prasad Gunasekaran; Kenric Leung; Nidhi Bindal; Harry Boutselakis; Minjie Ding; Sally Bamford; Charlotte Cole; Sari Ward; Chai Yin Kok; Mingming Jia; Tisham De; Jon W Teague; Michael R Stratton; Ultan McDermott; Peter J Campbell
Journal:  Nucleic Acids Res       Date:  2014-10-29       Impact factor: 16.971

10.  Clinical and pathogenic features of ETV6-related thrombocytopenia with predisposition to acute lymphoblastic leukemia.

Authors:  Federica Melazzini; Flavia Palombo; Alessandra Balduini; Daniela De Rocco; Caterina Marconi; Patrizia Noris; Chiara Gnan; Tommaso Pippucci; Valeria Bozzi; Michela Faleschini; Serena Barozzi; Michael Doubek; Christian A Di Buduo; Katerina Stano Kozubik; Lenka Radova; Giuseppe Loffredo; Sarka Pospisilova; Caterina Alfano; Marco Seri; Carlo L Balduini; Alessandro Pecci; Anna Savoia
Journal:  Haematologica       Date:  2016-06-30       Impact factor: 9.941

View more
  16 in total

Review 1.  Familial predisposition of myeloid malignancies: biological and clinical significance of recurrent germ line mutations.

Authors:  Hirotaka Matsui
Journal:  Int J Hematol       Date:  2017-06-19       Impact factor: 2.490

2.  Diagnosis and treatment of mixed phenotype (T-myeloid/lymphoid) acute leukemia with novel ETV6-FGFR2 rearrangement.

Authors:  Timothy Carll; Anand Patel; Benjamin Derman; Elizabeth Hyjek; Angela Lager; Pankhuri Wanjari; Jeremy Segal; Olatoyosi Odenike; Shiraz Fidai; Daniel Arber
Journal:  Blood Adv       Date:  2020-10-13

3.  Analysis of 153 115 patients with hematological malignancies refines the spectrum of familial risk.

Authors:  Amit Sud; Subhayan Chattopadhyay; Hauke Thomsen; Kristina Sundquist; Jan Sundquist; Richard S Houlston; Kari Hemminki
Journal:  Blood       Date:  2019-08-08       Impact factor: 22.113

Review 4.  Hematological Malignancies in Adults With a Family Predisposition.

Authors:  Tilmann Bochtler; Georg-Martin Haag; Sarah Schott; Matthias Kloor; Alwin Krämer; Carsten Müller-Tidow
Journal:  Dtsch Arztebl Int       Date:  2018-12-14       Impact factor: 5.594

Review 5.  Distinguishing constitutional from acquired bone marrow failure in the hematology clinic.

Authors:  Emma M Groarke; Neal S Young; Katherine R Calvo
Journal:  Best Pract Res Clin Haematol       Date:  2021-06-02       Impact factor: 3.670

Review 6.  Transcription factor mutations as a cause of familial myeloid neoplasms.

Authors:  Jane E Churpek; Emery H Bresnick
Journal:  J Clin Invest       Date:  2019-02-01       Impact factor: 14.808

7.  Heterozygous germ line CSF3R variants as risk alleles for development of hematologic malignancies.

Authors:  Amy M Trottier; Lawrence J Druhan; Ira L Kraft; Amanda Lance; Simone Feurstein; Maria Helgeson; Jeremy P Segal; Soma Das; Belinda R Avalos; Lucy A Godley
Journal:  Blood Adv       Date:  2020-10-27

Review 8.  The Biology of B-Progenitor Acute Lymphoblastic Leukemia.

Authors:  Kathryn G Roberts; Charles G Mullighan
Journal:  Cold Spring Harb Perspect Med       Date:  2020-07-01       Impact factor: 5.159

9.  Germline SAMD9 and SAMD9L mutations are associated with extensive genetic evolution and diverse hematologic outcomes.

Authors:  Jasmine C Wong; Victoria Bryant; Tamara Lamprecht; Jing Ma; Michael Walsh; Jason Schwartz; Maria Del Pilar Alzamora; Charles G Mullighan; Mignon L Loh; Raul Ribeiro; James R Downing; William L Carroll; Jeffrey Davis; Stuart Gold; Paul C Rogers; Sara Israels; Rochelle Yanofsky; Kevin Shannon; Jeffery M Klco
Journal:  JCI Insight       Date:  2018-07-26

10.  ETV6: A Candidate Gene for Predisposition to "Blend Pedigrees"? A Case Report from the NEXT-Famly Clinical Trial.

Authors:  Simona Bernardi; Mirko Farina; Camilla Zanaglio; Federica Cattina; Nicola Polverelli; Francesca Schieppati; Federica Re; Chiara Foroni; Michele Malagola; Andrew J Dunbar; Domenico Russo
Journal:  Case Rep Hematol       Date:  2020-01-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.